JULIUS MAXIMILIANS-UNIVERSITÄT WÜRZBURG Patent applications |
Patent application number | Title | Published |
20140121264 | MICRORNA (miRNA) AND DOWNSTREAM TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis. | 05-01-2014 |
20140072570 | ANTIBODIES OR FRAGMENTS THEREOF DIRECTED AGAINST A STAPHYLOCOCCUS AUREUS EPITOPE OF ISAA OR ISAB - The invention concerns antibodies or fragments thereof that are directed against a | 03-13-2014 |
20130018084 | MICRORNA (miRNA) AND DOWNSTREAM TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - In some embodiments, the present invention concerns antisense oligonucleotides against targets of miR-21. In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis. | 01-17-2013 |
20120288870 | Means for the inhibition of anti-beta1-adrenergic receptor antibodies - Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition. | 11-15-2012 |
20120288513 | Means for the inhibition of anti-beta1-adrenergic receptor antibodies - Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition. | 11-15-2012 |
20110071211 | MicroRNA (miRNA) And Downstream Targets For Diagnostic And Therapeutic Purposes - The present invention relates to a promoter region of a microRNA, the use of a microRNA, in particular miR-21, and related elements for the diagnosis and for the manufacture of a medicament for the treatment and/or prevention of fibrosis and/or fibrosis related diseases. Additionally, the invention concerns antisense oligonucleotides against targets of miR-21. A cell deficient for miR-21, the promoter region and targets of miR-21 and a knock-out organism thereof are also encompassed. Finally, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis. | 03-24-2011 |
20100010073 | MICRORNA (MIRNA) FOR THE DIAGNOSIS AND TREATMENT OF HEART DISEASES - The invention relates to microRNAs (miRNAs) for the diagnosis, prophylaxis and/or treatment of heart diseases. It relates in particular to SEQ ID No: 1 to SEQ ID No: 29 for the diagnosis, prophylaxis and/or treatment of heart diseases. In addition, the invention relates to the use of these sequences to produce a medicament for heart diseases and for the diagnosis thereof. Also encompassed are a method for the diagnosis of a heart disease, a kit and an expression vector comprising these sequences, a cell which contains the expression vector, and also a method for modulating a heart disease and a method for screening a pharmaceutically active compound for the treatment and/or prophylaxis of a heart disease. | 01-14-2010 |
20090293142 | Methods for increasing shoot-to-root ratio, seed production and resistance to diseases - The present invention is related to a method for increasing shoot-to-root ratio of a plant comprising the step of
| 11-26-2009 |
20090215675 | Means for the inhibition of anti-beta1-adrenergic receptor antibodies - The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II) whereby h is any integer from 0 to 2, preferably 1 or 2; c) a cyclic peptide of formula (III): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-xj-Cys-x-x-x-Pro-x-Cys-Cys-xi-Gln); (HI) whereby j is any integer from 0 to 4, preferably j=4; whereby i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i−6; and d) a peptide of formula (IV): Ala-x1-Cys-xm-Cys-x-x-x-Pro-x-Cys-Cys-xn-Gln, (IV) whereby 1 is any integer from 0 to 9, preferably any integer from 1 to 9, more preferably n=9; whereby m is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably m=4; whereby n is any integer from O to 6, preferably any integer from 1 to 6, more preferably n=6; whereby x is any amino acid, preferably any naturally occurring amino acid, more preferably any naturally occurring L-amino acid. | 08-27-2009 |